Induction of Voriconazole Metabolism by Rifampin in a Patient with Acute Myeloid Leukemia: Importance of Interdisciplinary Communication To Prevent Treatment Errors with Complex Medications

Documenti analoghi

• Safety of Voriconazole in a Patient with CYP2C9*2/CYP2C9*2 Genotype
  di: Geist, Marcus J.P., et al.
  Pubblicazione: (2006)
• The NK(1) receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma
  di: Egerer, Gerlinde, et al.
  Pubblicazione: (2010)
• Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype
  di: Scholz, Ina, et al.
  Pubblicazione: (2009)
• Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole
  di: Grün, Barbara, et al.
  Pubblicazione: (2009)
• Pharmacokinetics of Sulfobutylether-Beta-Cyclodextrin and Voriconazole in Patients with End-Stage Renal Failure during Treatment with Two Hemodialysis Systems and Hemodiafiltration
  di: Hafner, Verena, et al.
  Pubblicazione: (2010)